Down Syndrome Regression Disorder Clinical Trial

We are conducting a novel clinical trial of potential treatments for Down Syndrome Regression Disorder (DSRD) in people with Down syndrome, funded by the Eunice Kennedy Shriver National Institute for Child Health and Human Development (NICHD).  

Individuals with Down syndrome (DS) have an increased risk of numerous co-occurring conditions, including the rare neurological condition known as Down Syndrome Regression Disorder (DSRD). Individuals with a DSRD diagnosis often experience symptoms like catatonia or unresponsiveness, loss of speech, loss of ability to perform activities of daily living, hallucinations, delusions, and aggression. DSRD is more common in adolescents and young adults.

In this study, we are researching the safety and efficacy of three potential therapies: lorazepam, intravenous immunoglobulin (IVIG) and tofacitinib. 


We will assess two main outcomes: 

  • The safety of lorazepam, IVIG, and tofacitinib treatments 
  • The benefits of lorazepam, IVIG, and tofacitinib treatments on DSRD
Dr. Barry Martin listens with a stethoscope to a young man with Down syndrome

Curious to learn more? Expand each of the boxes below to keep reading.

Linda Crnic Institute for Down Syndrome

CU Anschutz

Research Complex II

12700 East 19th Avenue

Room 4014

Aurora, CO 80045


CMS Login